Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04201197 · ClinicalTrials.gov registry record · Phase 1
Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04201197: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT04201197 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04201197, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will evaluate drug-drug interactions between cannabis extracts containing Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450 pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9), dextromethorphan (CYP2D6), and midazolam (CYP3A).
Interventions
- DRUG Inje cocktail
- DRUG THC Cannabis extract
- DRUG THC/CBD Cannabis Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-11-10 |
| Est. Completion | 2022-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04201197
The ClinicalTrials.gov registry entry for NCT04201197 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Inje cocktail is the first listed.
NCT04201197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04201197 about?
NCT04201197 is a clinical study titled "Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs". This study will evaluate drug-drug interactions between cannabis extracts containing Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450 pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9), dextromethorphan (CYP2D6), and midazolam (CYP3...
What is the current status of trial NCT04201197?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-11-10. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT04201197?
The interventions under investigation include: Inje cocktail (DRUG), THC Cannabis extract (DRUG), THC/CBD Cannabis Extract (DRUG).
Who is sponsoring clinical trial NCT04201197?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.